癌睾丸抗原OY-TES-1在脑胶质瘤中的表达及其抗体血清学分析  

OY-TES-1 expression and serum immunoreactivity in glioma

作　　者：李希圣[1,2,3] 严峻[1] 罗彬[4] 贺菽嘉[4] 范蓉[5] 林永达[4] 罗昱[1] 肖绍文[1] 谢小薰[4,2] 

机构地区：[1]广西医科大学第一附属医院神经外科,广西南宁530021 [2]广西医科大学基础医学中心实验室,广西南宁530021 [3]滨州医学院附属医院神经外科,山东滨州256600 [4]广西医科大学组胚教研室,广西南宁530021 [5]广西中医学院组胚教研室,广西南宁530021

出　　处：《中国癌症杂志》2011年第9期671-674,共4页China Oncology

基　　金：国家自然科学基金(No:30760055、81060207);广西自然科学基金(No:0832144、2011GXNSFA018275);广西研究生教育创新计划资助项目资助(No:2008105981002M175、2010105981002M182)

摘　　要：背景与目的:胶质瘤是最常见的原发性恶性脑肿瘤,预后差,生存率低。近年来,以利用癌睾丸(cancer-testis,CT)抗原作为靶抗原行肿瘤免疫治疗已成为研究的热点,而OY-TES-1是CT抗原家族中的一员。本研究拟了解OY-TES-1在脑胶质瘤中的mRNA表达及其抗体出现情况,探讨将OY-TES-1应用于肿瘤免疫治疗及辅助诊断的可能性。方法:收集51例脑胶质瘤患者肿瘤组织标本及配套血清,107例健康人血清。通过RT-PCR,从mRNA水平研究OY-TES-1在脑胶质瘤组织中的表达;用酶联免疫吸附分析技术(enzyme linkedimmunosorbent assay,ELISA)检测患者及健康人血清OY-TES-1抗体;同时对OY-TES-1 mRNA的表达及血清抗体出现的临床意义做初步分析。结果:在脑胶质瘤患者中OY-TES-1 mRNA阳性率为80.4%(41/51),血清OY-TES-1抗体阳性率为15.7%(8/51),健康人血清则为阴性。OY-TES-1 mRNA的表达和血清抗体的出现均与脑胶质瘤患者的年龄、性别、病理分级、肿瘤大小等临床指标无关。结论:OY-TES-1在脑胶质瘤中存在较高的表达,并能引起部分患者的体液免疫反应,有望作为胶质瘤免疫治疗的靶抗原。Background and purpose：Glioma is the most common primary malignant brain tumor,with poor prognosis and low survival rate.In recent years,the cancer immunotherapy of taking cancer-testis（CT） antigen as the target antigen has been becoming a research hot spot,and OY-TES-1 antigen is a member of CT antigen family.This study was aimed to investigate the expression of OY-TES-1 mRNA and serum immunoreactivity in human glioma while also exploring the possibility of using OY-TES-1 as a target for immunotherapy and auxiliary diagnosis of glioma.Methods：Fifty one cases of tumor specimens from patients with glioma and matching sera,normal human sera in 107 cases were collected.OY-TES-1 expression in human glioma tissue was detected at mRNA level using RT-PCR.The presence of serum OY-TES-1 antibody in healthy donors and patients with gliomas was observed with ELISA.The clinical significance of OY-TES-1 mRNA expression and serum immumoreactivity was also analyzed.Results：The positive rate of OY-TES-1 mRNA expression in glioma was 80.4%（41/51）.15.7%（8/51） of patients＇ sera with glimas were OY-TES-1 antibody positive,while normal human serum was negative.No statistically significant correlation was found between OY-TES-1 mRNA expression,serum antibody and the clinical features of glioma including age,gender,tumor grade,and tumor size.Conclusion：OY-TES-1 shows high expression in glioma and can induce humoral immune response,suggesting that OY-TES-1 could be a target antigen for immunotherapy of glioma patients.

关 键 词：OY-TES-1 胶质瘤 免疫治疗 

分 类 号：R739.41[医药卫生—肿瘤]